
Abstract
Objective
To systematically review the efficacy and safety of prostacyclin analogs used to permit heparin anticoagulation during cardiopulmonary bypass (CPB) in patients with heparin-induced thrombocytopenia (HIT).
Design
We conducted a systematic review of PubMed and Scopus. Studies describing iloprost or epoprostenol use to permit heparinization during CPB were included. Efficacy and safety outcomes were analyzed by using descriptive statistics.
Setting
Published literature.
Participants
Patients with HIT or suspected HIT undergoing CPB with prostacyclin-assisted heparin anticoagulation.
Interventions
Iloprost or epoprostenol administration to inhibit platelet function and permit heparin anticoagulation during CPB, followed by protamine reversal.
Measurements and Main Results
Of 172 identified records, 23 studies encompassing 207 patients met inclusion criteria. Iloprost dosing was more variable and more frequently titrated using platelet function testing than epoprostenol dosing. Both agents permitted heparinization and protamine reversal. Norepinephrine, phenylephrine, vasopressin, and epinephrine use to manage prostacyclin-mediated hypotension was reported in 14 of 17 (82.3%), 4 of 18 (22.2%), 3 of 16 (18.8%), and 2 of 16 (12.5%) studies, respectively. Transfusion occurred in 122 of 207 patients (58.9%), thrombotic outcomes in 17 of 207 (8.2%), and mortality in 18 of 207 (8.7%). Only 1 of 207 patients (0.5%) experienced thrombosis during CPB; the remaining thrombotic events occurred after CPB.
Conclusion
Prostacyclin-assisted heparin anticoagulation can permit CPB and protamine reversal in patients with HIT requiring urgent surgery. Although prostacyclin-mediated hypotension frequently necessitates vasopressor support, intraoperative thrombotic events appear uncommon.
We use cookies to provide you with the best possible user experience. By continuing to use our site, you agree to their use. Learn more